23:49 , Aug 16, 2019 |  BioCentury  |  Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade. On February 22, 2019, China’s National...
01:44 , Aug 16, 2019 |  BC Innovations  |  Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
22:07 , Aug 14, 2019 |  BC Extra  |  Clinical News

Aug. 14 Clinical Quick Takes: Lynparza boosts ovarian cancer survival in first-line setting; plus Novavax, Gritstone and Solid

Lynparza extends PFS in first-line ovarian cancer  Lynparza olaparib plus bevacizumab as first-line maintenance therapy met the primary endpoint of significantly extending progression-free survival (PFS) vs. standard-of-care bevacizumab alone in advanced ovarian cancer patients in...
23:03 , Aug 9, 2019 |  BC Extra  |  Company News

Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos' momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors...
00:06 , Aug 3, 2019 |  BioCentury  |  Emerging Company Profile

Bringing CAR T to India

A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in India for about $50,000 per treatment. That cost, which...
05:29 , Jul 31, 2019 |  BioCentury  |  Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
22:07 , Jul 30, 2019 |  BC Extra  |  Company News

Keytruda sales show how Merck can compete in China

Despite local competition from cheaper PD-1 inhibitors, Keytruda continues to drive Merck's growth in China and its revenue globally. The immuno-oncology drug brought in $2.6 billion in global sales for the quarter, up 63% from...
22:43 , Jul 25, 2019 |  BC Innovations  |  Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
22:01 , Jul 19, 2019 |  BioCentury  |  Product Development

Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing

The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite. Human capital was the driver behind Gilead Sciences...
00:16 , Jul 19, 2019 |  BC Innovations  |  Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...